Clinical trialsCompany release

Precision BioSciences doses first Duchenne patient as hepatitis B data head to AASLD

🇺🇸 Precision Biosciences Inc (DTIL) · Tue 03 Nov 2026

The gene-editing company reports $108 million in cash, expected to last through 2028, alongside a first dosing in its DMD study and a late-breaking HBV presentation.

Precision BioSciences (Nasdaq: DTIL) reported third-quarter 2026 results and a business update on 3 November, highlighting clinical progress in two gene-editing programmes.

The company has dosed the first patient with PBGENE-DMD in the Phase 1/2 FUNCTION-DMD study in Duchenne muscular dystrophy. It is targeting initial safety data by the end of 2026.

Data from PBGENE-HBV, tested in the ELIMINATE-B trial in chronic hepatitis B, will be given as a late-breaking oral presentation on 8 November at the Liver Meeting of the American Association for the Study of Liver Diseases (AASLD).

Precision reported cash of $108 million. It expects this to fund operations through 2028. The summary available does not include further financial detail or trial results.

What it means for your team

  • Initial safety data from FUNCTION-DMD, due around year-end 2026, will be the first read on this Duchenne gene-editing approach and a point for safety-monitoring teams to watch.
  • The 8 November AASLD late-breaking presentation is the next opportunity to review PBGENE-HBV data from ELIMINATE-B.
  • The cash runway to 2028 suggests the company can continue both early-stage programmes without immediate new financing, according to its own guidance.

Company's press release (SEC filing): Precision Biosciences Inc ↗

Article written by VigiEye from the official source (Precision Biosciences Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →